Next Generation Sequencing Market is Poised to Grow at a CAGR of 18.5%, Attributed to Rise for Personalized Medicine

August 08, 2024 10:05 PM AEST | By EIN Presswire
 Next Generation Sequencing Market is Poised to Grow at a CAGR of 18.5%, Attributed to Rise for Personalized Medicine
Image source: EIN Presswire

WESTFORD, MASSACHUSETTS, UNITED STATES, August 8, 2024 /EINPresswire.com/ -- Next Generation Sequencing Market size was valued at USD 7.82 Billion in 2022 and is poised to grow from USD 9.27 Billion in 2023 to USD 36.04 Billion by 2031, growing at a CAGR of 18.5% in the forecast period (2024-2031).

Download a detailed overview:
https://www.skyquestt.com/sample-request/next-generation-sequencing-market

Next-generation sequencing uses massive parallelism to sequence millions, if not billions, of DNA strands. This method is also known as high throughput sequencing. Compared to NGS, Sanger genome sequencing depends more on fragment-cloning procedures. NGS is growing due largely to the global push for scalability and personalized medicine systems. Next-generation sequencing (NGS) techniques have enabled comprehensive and wide-ranging characterization of genetic data, which has led to improvements in accurate drug treatments and regimens. As the demand for accurate diagnostic and therapeutic increases more NGS platforms are being deployed, and industrial innovation is being encouraged.

A Paradigm Shift in Genetic Analysis Technologies

The following are the key Next Generation Sequencing Trends that will shape the growth of the market in the next 5 years

in December 2023, the beta version of TurBOT was released, due to a collaboration of Oxford Nanopore and Tecan. By the first quarter of 2024, products are anticipated to be delivered to the buyers. The TurBOT's potential includes the ability to do base calling, data analysis, sample preparation, and automated extraction of several samples from a single instrument.

This invention is expected to democratize access to advanced sequencing tools, allowing researchers and clinicians globally to do rapid and comprehensive genetic analysis. TurBOT's scalability, which enables it to handle several samples simultaneously significantly increase laboratory throughput and efficiency in the next 4-5 years which results in cheaper costs and faster scientific discoveries in fields that includes agriculture, customized medicine, and environmental science. By offering more easily accessible and efficient genetic analysis tools, TurBOT is positioned to ignite new advances in the research of genetic disorders.

Request Free Customization of this report:
https://www.skyquestt.com/speak-with-analyst/next-generation-sequencing-market

Innovative Solutions for Gene Therapy: NewBiologix Unveils Cutting-Edge NGS and Optical Mapping Platform

In April 2024, NewBiologix, a cutting-edge technology company based in Lausanne, Switzerland, announced the launch of a cutting-edge platform designed to solve manufacturing problems associated with gene therapy. With the combination of Next-Generation Sequencing (NGS) and optical mapping technologies, this new solution offers a comprehensive suite of services tailored for genomic research. Through the combination of these advanced methods, NewBiologix aims to provide the biopharmaceutical industry with a very feasible and efficient solution, signifying a significant breakthrough in biotech capabilities. By simplifying processes this platform promises to increase accuracy and fasten the creation of therapeutic advancements in healthcare.

Innovative Trends and Strategies: Future of Next Generation Sequencing

Illumina and the African Society for Laboratory Medicine inked a Memorandum of Understanding in December 2023 to combat infectious diseases across Africa.

In January 2023, Leader in population genomics i.e. QIAGEN and California-based Helix, signed collaboration to improve companion diagnostics for next generation sequencing.

Thermo Fisher Scientific unveiled the CE-IVD-marked Ion Torrent Genexus Dx Integrated Sequencer, a next-generation sequencing (NGS) platform, in March 2022. This automated device is expected to generate results within a day.

View report summary and Table of Contents (TOC):
https://www.skyquestt.com/report/next-generation-sequencing-market

Final Presumption into the NGS Market

Concluding NGS market, technological advancements and growing applications across a range of industries, including healthcare, and agriculture, are driving the rapid growth. NGS is now more widely available and significant than in the past as industry participants can boost sequencing accuracy, throughput, and cost-effectiveness through constant innovation.

Related Report:
Artificial Intelligence Market

About Us:
SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.

We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization has expanded our reach across North America, Europe, ASEAN and Asia Pacific.

Visit Our Website: https://www.skyquestt.com/

Mr. Jagraj Singh
Skyquest Technology Consulting Pvt. Ltd.
+1 351-333-4748
email us here
Visit us on social media:
LinkedIn


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.